
==== Front
Cell Death Differ
Cell Death Differ
Cell Death and Differentiation
1350-9047
1476-5403
Nature Publishing Group UK London

39068204
1350
10.1038/s41418-024-01350-1
Review Article
Ferroptosis-based advanced therapies as treatment approaches for metabolic and cardiovascular diseases
http://orcid.org/0000-0002-7670-2055
Maremonti Francesca 123
http://orcid.org/0000-0002-9728-1413
Tonnus Wulf 13
http://orcid.org/0000-0003-2876-1453
Gavali Shubhangi 123
Bornstein Stefan 3456
Shah Ajay 7
http://orcid.org/0000-0003-2927-7225
Giacca Mauro 7
http://orcid.org/0000-0001-6287-9725
Linkermann Andreas andreas.linkermann@ukdd.de

1238
1 https://ror.org/042aqky30 grid.4488.0 0000 0001 2111 7257 Division of Nephrology, Medical Clinic III, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany
2 grid.7700.0 0000 0001 2190 4373 Department of Medicine V, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany
3 https://ror.org/04za5zm41 grid.412282.f 0000 0001 1091 2917 Department of Internal Medicine 3, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
4 https://ror.org/0220mzb33 grid.13097.3c 0000 0001 2322 6764 Diabetes and Nutritional Sciences, King’s College London, London, UK
5 https://ror.org/042aqky30 grid.4488.0 0000 0001 2111 7257 Center for Regenerative Therapies, Technische Universität Dresden, Dresden, Germany
6 https://ror.org/05ke5hb07 grid.507329.a Paul Langerhans Institute Dresden of Helmholtz Centre Munich at University Clinic Carl Gustav Carus of TU Dresden Faculty of Medicine, Dresden, Germany
7 https://ror.org/0220mzb33 grid.13097.3c 0000 0001 2322 6764 King’s College London British Heart Foundation Centre, School of Cardiovascular & Metabolic Medicine and Sciences, London, UK
8 https://ror.org/05cf8a891 grid.251993.5 0000 0001 2179 1997 Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY USA
27 7 2024
27 7 2024
9 2024
31 9 11041112
12 5 2024
10 7 2024
18 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Ferroptosis has attracted attention throughout the last decade because of its tremendous clinical importance. Here, we review the rapidly growing body of literature on how inhibition of ferroptosis may be harnessed for the treatment of common diseases, and we focus on metabolic and cardiovascular unmet medical needs. We introduce four classes of preclinically established ferroptosis inhibitors (ferrostatins) such as iron chelators, radical trapping agents that function in the cytoplasmic compartment, lipophilic radical trapping antioxidants and ninjurin-1 (NINJ1) specific monoclonal antibodies. In contrast to ferroptosis inducers that cause serious untoward effects such as acute kidney tubular necrosis, the side effect profile of ferrostatins appears to be limited. We also consider ferroptosis as a potential side effect itself when several advanced therapies harnessing small-interfering RNA (siRNA)-based treatment approaches are tested. Importantly, clinical trial design is impeded by the lack of an appropriate biomarker for ferroptosis detection in serum samples or tissue biopsies. However, we discuss favorable clinical scenarios suited for the design of anti-ferroptosis clinical trials to test such first-in-class compounds. We conclude that targeting ferroptosis exhibits outstanding treatment options for metabolic and cardiovascular diseases, but we have only begun to translate this knowledge into clinically relevant applications.

Subject terms

Translational research
Cardiovascular diseases
Metabolic disorders
https://doi.org/10.13039/501100001659 Deutsche Forschungsgemeinschaft (German Research Foundation) TRR205 SPP2306 LI 2107/10-1 IRTG2251 Maremonti Francesca Linkermann Andreas issue-copyright-statement© ADMC Associazione Differenziamento e Morte Cellulare 2024
==== Body
pmcFacts

Ferroptosis contributes to metabolic and cardiovascular diseases and their complications.

Ferroptosis inhibition represents a promising therapeutic option for several acute diseases.

Several classes of ferroptosis inhibitors (ferrostatins) are available.

No anti-ferroptotic therapy has been tested in clinical trials.

Open questions

How does ferroptosis contribute to metabolic and cardiovascular diseases?

What is a reliable biomarker for ferroptosis?

How can the promising preclinical studies be translated into effective clinical therapies?

What is the physiological relevance of ferroptosis, and how can potential side effects of ferrostatins be predicted?

Introduction

Cell death exhibits a hallmark of many diseases. Clinically relevant regulated cell death encompasses apoptosis [1], necroptosis [2], pyroptosis [3] and as an entirely different entity, iron-catalyzed necrosis [4, 5], referred to as ferroptosis [6]. All of these pathways result in a cataclysmic burst [7] mediated at least partially by oligomerization of the plasma membrane protein ninjurin-1 (NINJ1) [8–10]. This ultimate rupture of the plasma membrane defines “necrosis” and is inevitably associated with the release of intracellular content referred to as damage associated-molecular patterns (DAMPs) [11–13] which result in the activation of immune cells in an event defined as necroinflammation [14, 15]. It is beyond the scope of this review to discuss the details of these terms apart from the definition of ferroptosis, and the interested reader is referred to the above cited review articles. However, the potential applications for inhibitors of ferroptosis (ferrostatins) are of particular importance in metabolic and cardiovascular diseases and their complications. Endocrine disorders, with diabetes mellitus as the most prominent example, are particularly susceptible to ferroptosis, and steroid hormones [16, 17] as well as cholesterol metabolites [18, 19] are emerging as important regulators of ferroptosis [20]. Cardiovascular complications, such as myocardial infarction, acute kidney injury and stroke are particularly common in diabetic patients [21], and the associated ischemia-reperfusion injury (IRI) has been a prototype disease model for ferroptosis [5, 22–24]. With lipid peroxidation representing a typical feature of ferroptosis, it is not surprising that fatty liver diseases and IRI in the liver are driven by ferroptosis as well [25, 26]. Please note that while intercellular ferroptosis propagation has been described [27, 28], it remains entirely unclear how cell death propagation between cells is regulated. It is unclear until today to which extent cell death propagation is a specific feature of ferroptosis. We will highlight the potential of advanced therapies targeting ferroptosis and start by defining ferroptosis as iron-catalyzed necrosis.

Part 1—the definition of ferroptosis

For the purpose of this review article, we define ferroptosis as iron-catalyzed plasma membrane rupture. Fenton reactions lead to the generation of reactive oxygen species that may be controlled by cytosolic redox systems such as the thioredoxin reductase reaction. The thioredoxin-mediated redox signaling represents an antient NAD(P)H-dependent biological reaction pattern, sometimes referred to as the redox metabolome [29], and has been described to be involved in plant immunity [30]. Clearly, the thioredoxin (TRX)-system is involved in the pathophysiology of diabetes as well [31, 32]. Failure of such NAD(P)H-dependent systems to mitigate the cytosolic ROS-concentration triggers the lipid peroxidation and the typical chemical reactions of ferroptosis [33] that are opposed by ferroptosis surveillance enzymes. The best studied system is the glutathione peroxidase 4, a GSH-metabolizing selenocysteine essential for vertebrate life [34, 35]. GPX4 requires direct contact with the plasma membrane to fully function, and mutations in the lipid bilayer anchoring loop of GPX4 result in remarkable dysfunction. Besides GPX4, GSH-independent enzymes have been described to be capable of replacing GPX4 function, at least at the cellular level. Ferroptosis-suppressor protein 1 (FSP1) relies on CoQ10 to prevent lipid peroxidation [36, 37], while other systems, such as membrane-bound O-acyltransferase domain-containing 1 and 2 (MBOAT1/2) are less well understood [38]. With all the chemistry and the ferroptosis surveillance systems studied in detail, the events that connect lipid peroxidation with subsequent rupture of the plasma membrane (necrosis) are almost entirely elusive. Although not all forms of ferroptosis (e.g., RSL3-induced cell death) appear to require ninjurin-1 (NINJ1) [39], recent data have suggested a critical involvement of this molecule to execute the cataclysmic burst of the plasma membrane in ferroptosis through NINJ1 oligomerization [10]. The details of the regulated mechanisms of NINJ1 membrane organization and oligomerization are lacking any concept until today, although it has recently been demonstrated to involve the cutting and releasing of membrane discs [40]. However, inhibition of NINJ1 oligomerization using a monoclonal antibody has been recently demonstrated to prevent other forms of regulated necrosis, such as necroptosis and pyroptosis from their ultimate execution and at least parts of their immunogenicity [9]. Figure 1 demonstrates our current understanding of the ferroptosis-defining cellular reactions. Based on the definition of ferroptosis introduced in Fig. 1, ferroptosis can be interfered with at various levels. Similarly, all conditions that shift the balance toward a higher ratio of lipid peroxidation to ferroptosis surveillance capacity will decrease the threshold for ferroptosis.Fig. 1 The definition of ferroptosis.

By definition, ferroptosis requires an iron-catalyzed reaction with oxygen (Fenton reaction) which is the origin of the ferroptosis reaction cascade. In an intermediate step, reactive oxygen radicals, such as H2O2 and higher order radicals form as direct and indirect consequences of Fenton reactions. In most cells, thioredoxin (TRX) scavenges such radicals and is immediately regenerated by the potent selenoprotein thioredoxin reductase (TRXRD1) in an NAD(P)H consuming reaction. If such reactive oxygen radicals cannot be controlled, lipids in the plasma membrane (and other intracellular membranes) become peroxidized (Lipid peroxidation). Peroxyl versions of plasma membrane lipids are converted to alcohols by the classical ferroptosis surveillance systems, such as glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1) and others. Lipophilic radical trapping agents compete with lipids for peroxidation, thereby shifting the balance toward lower concentrations of lipid peroxides. Through entirely unknown mechanisms, and potentially involving several undefined intermediate steps, plasma membrane lipid peroxidation results in the oligomerization of pore forming ninjurin-1 (NINJ1) molecules that are required for the cataclysmic burst of the plasma membrane. The rupture of the plasma membrane defines ferroptosis as a necrotic event.

Part 2—approaches to interfere with ferroptosis

According to the definition introduced in Fig. 1, ferroptosis may be classified into four subcellular stages. We have chosen to allocate inhibitors of ferroptosis (ferrostatins) into four according classes. Ferroptosis inhibitors (ferrostatins) may be subclassified in at least four classes according to their mechanisms of action. Figure 2 demonstrates how these classes relate to the ferroptotic cellular chemical reaction patterns and Table 1 lists several but not all prominent examples according to their mechanism of action. As one example of an innovative approach, the use of selenium-containing Tat-proteins have claimed to protect (e.g., in a stroke model [41]), but the transition of this selenium containing Tat SelPep to other ferroptosis models remains to be demonstrated [41], so we did not add this approach as an individual class of ferroptosis inhibitors here. Other advanced therapies aim at harnessing small non-coding RNAs [42], particularly for cardiovascular diseases, but RNA interference may even sensitize to ferroptosis [43].Fig. 2 The classes of ferroptosis inhibitors (ferrostatins).

Four stages have been defined that characterize the ferroptotic reaction cascade, all of which potentially can be interfered with. In the initial step, Fenton reactions can be targeted by iron chelators, provided that specific cellular compartments, such as the lysosome or the ER, can be accessed by the compound. The default example of this class is deferoxamine (DFO). As soon as free radicals have formed, radical trapping agents (RTAs) may interfere with these short-lived highly reactive products as long as they are available in direct proximity to the radicals. Lipid peroxidation is competed with by lipophilic radical trapping antioxidants (lipophilic RTAs). Prominent examples of this most commonly studied class of ferrostatins are ferrostatin-1 (Fer-1), liproxstatin-1 (Lip-1), 16-86 etc. The ultimate step of plasma membrane rupture can be interfered with by monoclonal antibodies against ninjurin-1 (NINJ1). This step is not specific for ferroptosis, but was initially demonstrated to be required for necroptosis, pyroptosis and even secondary necrosis following apoptosis.

Table 1 Prominent but incomplete members of the four classes of ferroptosis inhibitors.

	Examples	Mechanism	
Class I	- Deferoxamine [45, 63]

- Deferiprone [126]

- Deferasirox [127]

	Iron chelation to inhibit generation of hydroxyl radicals	
Class II	- Hydropersulfides [50]

- UAMC-3203 [53]

- Nec-1f [28]

- Omeprazole [54]

- Rifampicin [54]

- Promethazine [54]

- Carvedilol [54]

- Propranolol [54]

- 7-dehydrocholesterol (7-DHC) [18, 19]

- indole-3-pyruvate (I3P) [51]

	Detoxify hydroxyl radicals and prevent protein sulfur peroxidation	
Class III	- Fer-1 [45]

- Lip-1 [34]

- Vitamin E [56]

- Vitamin K [57]

- CoQ10 [36, 37]

	Interrupt propagation of lipid peroxidation by detoxifying lipid peroxyl radicals	
Class IV	- Monoclonal NINJ1-antibody [9, 10]

- Glycine [61, 64, 128]

	Prevent cataclysmic burst of plasma membrane	

Class 1 ferrostatins: iron chelators

The requirement of iron is part of the definition of ferroptosis. Erastin was already demonstrated in 2003 to induce rapid cell death in cancer cells in cell culture experiments [44]. Iron chelation using 100 µM deferoxamine (DFO) was demonstrated to protect HT1080 cells from erastin-induced cell death in the first figure of the first ever publication ferroptosis [45]. In the same set of experiments, addition of exogenous free iron potentiated erastin-induced cell death while addition of other divalent metals such as Cu2+, Mn2+, Ni2+, and Co2+ did not [45]. However, long before the term ferroptosis was coined, a body of literature on the role of iron and iron chelation in cell death had accumulated as recently reviewed [46]. Importantly, the Fenton chemistry might occur in highly compartmentalized areas of the cell, and iron chelators, chemically, might not reach such areas (e.g., the complex I and III in mitochondria), and therefore might fail to inhibit ferroptosis even though it is mediated by Fenton reactions. While some literature exists that demonstrates iron chelation to protect in disease models, e.g., of traumatic brain injury [47], clinical trials using iron chelators failed to provide clear protective effects e.g., in acute kidney injury [48, 49], potentially because of the specific pharmacodynamics of DFO and derivatives. It will be challenging to design tissue-penetrant iron chelators to target the very upstream reaction of ferroptosis without significant side effect.

Class 2 ferrostatins: radical trapping agents that function in the cytosolic compartment

Radicals as a result of Fenton reactions may be scavenged by non-lipophilic radical trapping antioxidants. One endogenous example of this class may be hydropersulfide [50]. Additionally, I3P is generated by the secreted amino acid oxidase interleukin-4-induced-1 (IL4i1) the activity of which therefore creates an anti-ferroptosis environment [51, 52]. Pharmacologically, the compound UAMC-3203 [53] was demonstrated to have a favorable PK profile because it is less lipophilic, and therefore appears to function as a particularly potent ferrostatin. Along similar lines, the tissue PK profile of the dual inhibitor of necroptosis and ferroptosis Nec-1f suggests hydrophilic properties while functioning as a low-potency ferrostatin [28]. Several other compounds that have entered clinical routine, such as omeprazole, rifampicin, promethazine, carvedilol and propranolol have been demonstrated to function as ferroptosis inhibitors, while all of these drugs exhibit favorable tissue distribution and therefore might be repurposed as ferrostatins [54]. In this context, it is worth mentioning that rifampicin resistance is a paramount problem in the treatment of mycobacteria [55] (see below).

Class 3 ferrostatins

Lipophilic radical trapping antioxidants

Lipophilic radical trapping antioxidants are by far the best studied class of ferrostatins, and the expanding list of lipophilic RTAs is too long to be listed here. However, ferrostatin-1 (Fer-1) is the first-in-class compound but was ascribed an unfavorable half-life and poor tissue PK [45]. Despite these properties, this small molecule, against expectations, protected mice in several preclinical models including the kidney IRI model which may prolong the half-life of Fer-1 by reduction of its renal excretion [27]. Liproxstatin-1 (Lip-1) protected GPX4-deficient mice from death by acute renal tubular necrosis and therefore is considered a particularly suitable ferrostatin for in vivo research [34]. Vitamin E [56] and Vitamin K [57] are the best studied endogenous representatives of this class of compounds, and at least for Vitamin K, protection from ischemia-reperfusion injury has been reported [57]. Therapeutic supplementation of Vitamin E was tested in patients with nonalcoholic steatohepatitis and was associated with significant improvement compared to placebo or pioglitazone, which was also tested in that trial [58]. While a role for ferroptosis may be questioned in nonalcoholic steatohepatitis, this trial is valuable as it carefully assessed the potential side effect profile of a 96-week episode of ferroptosis inhibition in humans without major untoward effects reported [58]. Vitamin K2 (menaquinone-7) was tested at a dose of 360 µg/day to improve the serum calcification propensity and arterial stiffness in kidney transplant recipients in a single center, randomized, double-blind trial, a 12-week supplementation period, all three severe adverse events were reported to have occurred unrelated to the study medication [59]. Metabolites, such as 7-dehydrocholesterol (7-DHC) [18, 19] can also function as radical trapping agents that oppose ferroptosis. In the case of 7-DHC, genetic deletion of 7-DHC reductase (7-DHCR) was found to protect in two independent ferroptosis screening approaches [18, 19]. While 7-DHCR itself does not function as an RTA, the substrate does. Therefore, the activity level of 7-DHCR indirectly decreases ferroptosis sensitivity, and 7-DHC could be employed therapeutically. The present data on 7-DHC additionally suggest that it could inhibit phospholipid peroxidation both in the FENIX assay (DTUN-induced lipid peroxidation) and iron/ascorbate-induced lipid peroxidation [18, 19]. Therefore, 7-DHC suppresses ferroptosis by diverting the “propagation” of peroxyl radical-mediated damage from phospholipid components to its sterol core, rather than preventing the “initiation” of lipid peroxidation.

Class 4 ferrostatins: inhibitors of the cataclysmic burst of the plasma membrane

Until today, only NINJ1-oligomerization inhibitors can be allocated to this class [10]. However, it remains to be determined if this approach would inhibit ferroptotic cell death alongside with necroptosis and pyroptosis, but given the overlapping final steps of these pathways before plasma membrane rupture [60], we consider it likely that NINJ1-interference functions as ferroptosis inhibition. Apart from NINJ1, it is known that glycine protects isolated kidney tubules from LDH release [61, 62], and that this effect at least partially contains a ferroptotic component [63]. At least partially, glycine suppresses necrotic cell death by inhibition of NINJ1 membrane clustering [64]. Since glycine does not affect lipid peroxidation directly, it might function in a NINJ1-related way, potentially preventing plasma membrane discs from being shed off the membrane, relating to a recently published concept [40]. Finally, glycine protects kidney tubules from plasma membrane rupture, but the energetic function of these tubular cells is severely compromised, indicating that the cells may be “metabolically dead” while the membrane remains intact [62].

Conditions that sensitize to ferroptosis

It is beyond the scope of this review to mention the long list of ferroptosis inducers (FINs) that are developed mainly with the intention to drive cancers into ferroptosis. Some commonly used drugs, however, sensitize to ferroptosis by affecting the endogenous surveillance systems of ferroptosis (compare Fig. 1). As an example, dipeptidase-1 (DPEP-1) activity decreases the intracellular GSH pool, thereby decreasing the activity of GPX4. Commonly used steroids, such as dexamethasone and cortisol, through the glucocorticoid receptor, increase DPEP-1 expression and thereby sensitize to ferroptosis and deteriorate ischemia-reperfusion injury [17, 65]. Another recently discovered mechanism of sensitization to ferroptosis involves the emerging treatment with siRNAs. While the approach offers great opportunities to directly target specific proteins by in vivo post-transcriptional gene silencing [66], siRNAs, just like viral RNAs, can be sensed by the mitochondrial protein MAVS [67] and functionally sensitize to ferroptosis independent of the knockdown of the target protein [43]. Most likely by yet another independent mechanism, drugs that induce cell cycle arrest sensitize to ferroptosis and therefore my contribute to its success in tumor therapy [68]. With a perspective to cardiovascular diseases, an oxygen enriched environment, such as it occurs during the postnatal phase, itself induces a cell cycle arrest [69] and thereby may contribute to sensitizing cardiomyocytes to ferroptosis. Finally, iron-selective prodrugs can activate ferroptosis [70], and iron addition of cancers and persister cells in particular [71], can be interfered with in many pharmacological ways and defines a therapeutic approach [72].

Part 3—metabolic and cardiovascular diseases driven by ferroptosis

The oxygen burst that occurs at the birth of vertebrates creates an environment of hyperoxia in cardiomyocytes which results in cell cycle arrest [69]. It is currently unclear to which extent this potentially priming metabolic event contributes to the outstanding sensitivity of the heart to ferroptosis [73] in diseases such as myocardial infarction [74] and cardiomyopathy [75, 76]. However, the cardiovascular system and its complications emerged as a prime target for treatments with ferrostatins. This also involves the common complications of atherosclerosis, many of which share the common pathophysiological principle of ischemia-reperfusion injury (IRI). Along these lines, kidney IRI has become a classical in vivo setting to study ferroptosis inhibitors [22, 77–79], but liver IRI [34, 57, 80–83], stroke models [84–87] and myocardial infarction and heart failure models [23, 88–96] have been demonstrated to involve ferroptosis and can be improved by ferroptosis inhibition. Consequences of cardiovascular disease-induced necrosis may affect the cardiovascular system itself, as exemplified by cardiac arrythmias. While indeed one study indicated that ferroptosis inhibition may reduce the frequency of atrial fibrillation [97], this topic needs to be studied in much more detail. Most of the existing literature in this field that we will review in the following paragraphs, however, focused on atherosclerosis and patients at risk for cardiovascular complications, such as individuals suffering from diabetes mellitus and/or chronic hemodialysis treatment.

The major risk factor for cardiovascular complications, besides cigarette smoking and uncontrolled elevated blood pressure, is diabetes mellitus. As illustrated in Fig. 3, the pathophysiology of disease progression during type 1 diabetes mellitus (T1DM) involves ferroptosis at several different stages. First, pancreatic beta cells, like other hormone producing cells [98, 99], are known to be extraordinarily sensitive ferroptosis, potentially further driven by viral infections [100–103]. Second, atherosclerosis as a major hallmark of diabetic organ complications, involves a necrotic plaque formation the origin of which may comprise of ferroptotic cell death [104–107], potentially driven by cholesterol crystals. Finally, all mentioned ferroptosis-driven IRI complications (Fig. 3c) apply to the classical cardiovascular end points of diabetic patients. T1DM patients are commonly subjected to combined pancreas-kidney transplantation during the process of which ferroptosis and IRI can occur again (see below). Even though the specific literature on ferroptosis in cardiovascular diseases in the setting of diabetes mellitus is limited, some evidence suggests that endoplasmatic reticulum stress and associated ferroptosis are particularly important in myocardial IRI [108].Fig. 3 The role of ferroptosis in the pathophysiology of diabetes mellitus.

a Insulin-producing pancreatic beta cells are highly sensitive to ferroptosis, and their loss is considered the origin of type 1 diabetes mellitus (T1DM), a classical example of a metabolic disease. Diabetes mellitus, not restricted to T1DM, is frequently associated with cardiovascular complications many of which originate from progressive atherosclerotic plaque formation. b Cholesterol crystals and cells of both the innate and the adaptive immune systems are involved in atherosclerotic plaque formation, and ferroptosis may be amongst the many pathways that contribute to necrotic debris formation in these plaques. c Upon atherosclerotic plaque rupture, commonly observed in patients suffering from metabolic syndrome which includes diabetes mellitus, myocardial infarction, stroke and other disorders associated with a perfusion-deficit or ischemia-reperfusion injury may occur. The necrosis observed in such tissues, particularly its cell death propagation, is known to be driven by ferroptosis. Treatment with various classes of ferrostatins was demonstrated to protect end organ damage in respective experimental models.

Prospective cohort studies have investigated cardiovascular diseases and iron uptake in the patient´s diets since the HPFS [109] and NHANES-I [110] studies in 1994. The results of these observational trials have indicated that individuals with relatively high heme iron intake exhibit an increased cardiovascular risk, most prominently represented by increased hazard ratios for coronary heart disease [111]. As it is beyond the scope of this article, the interested reader may be referred to recent reviews on iron uptake in cardiovascular disease [112]. We argue that given the potential deterioration of ferroptosis and additional preclinical experimental data on iron toxicity [53], additional iron supplementation should be used with caution in patients with high risk of cardiovascular complications. This appears to be particularly important for chronic dialysis patients who have lost every trace of renal function, including the production of erythropoietin as the cause of renal anemia. Guidelines for these patients still recommend iron supplementation [113], even though it is well known that cardiovascular complications in dialysis patients are the leading cause of death [114–116]. Given the importance of cardiovascular complications for this patient cohort, we suggest that intravenous iron supplementation must be tested in longitudinal prospective randomized controlled clinical trials designed for cardiovascular complications as the primary end point. In our opinion, without such clinical trials, supplementation of iron to supranormal levels cannot be justified in dialysis patients as long as translational scientific data on ferroptosis are taken into consideration.

Finally, a condition associated with cardiovascular diseases is chronic kidney disease (CKD). It is beyond the scope of this review to list details of CKD pathophysiology. However, most kidney researchers and nephrologists have accepted the general model of acute kidney injury (AKI)-to-CKD transition, the central hypothesis of which interprets CKD progression as repeatedly occurring episodes of AKI which lead to acute tubular necrosis and nephron loss [117]. While it is clear that AKI is mediated by ferroptosis in many scenarios, CKD is commonly associated with Vitamin K deficiency [118] which might further sensitize CKD patients to additional episodes of AKI, thereby driving a vicious circle. Outside the ferroptosis research field, exhaustion of Vitamin K is mostly discussed as a shortage of Vitamin K dependent protein (CKDP) expression that contributes to vascular calcification in CKD patients. These findings are based on the “Rotterdam Study” that demonstrated high menaquinone intake in the diet to be associated with reduced risk of coronary heart disease [119, 120]. In conclusion, all these studies point to a superiority upon ferroptosis inhibition in cardiovascular diseases, and clinical trials with a clearer focus on ferroptosis rather than general vascular outcomes are indicated to assess the clinical applicability of anti-ferroptosis agents. In the following section, we will discuss potential clinical trials to address this question.

Part 4—considerations on potential clinical trial designs for first-in-class ferroptosis inhibitors

As outlined in the previous sections, many clinical conditions may benefit from treatment with ferrostatins. However, clinical trial design may be limited because of the lack of a specific biomarker for ferroptosis in tissues. To consider possible clinical trials despite these circumstances, we recommend to consider the following examples:

The ideal clinically emerging scenario requires a situation in which ferroptosis can be predicted. Solid organ transplantation exhibits one such example (Fig. 4a). This situation offers two possibilities for the application of ferrostatin. First, the brain-dead donor could be treated. Second, the graft, once removed from the donor and perfused in an isolated perfusion device, could be applied with ferrostatins. In both cases, the organ recipient would need to be investigated most carefully for potential side effects. As mentioned above, kidney-transplant recipient patients were already treated with supplementation of Vitamin K, but this was later after transplantation with an entirely different question on progression of calcification [59]. Of course, a stably kidney transplanted patient regularly is on an entirely different and much less aggressive immunosuppressive medication compared to a freshly transplanted individual. And even though the first 3 months following solid organ transplantation may appear arguably different compared with the later life of a successfully transplanted patient, that trial, however, included a kidney transplant cohort without reporting medication-specific side effects [59]. This trial included patients with an estimated glomerular filtration rate (eGFR) as low as 20 ml/min/1.73 m². This also demonstrates that it may be considered safe to treat patients suffering from acute and chronic kidney injury.Fig. 4 Manifest clinical trials for ferroptosis inhibitors.

a Ferroptosis inhibition employing a kidney perfusion device upon solid organ transplantation. b Ferroptosis inhibitor application before cardiac surgery. c Ferroptosis inhibition as a strategy to prevent acute kidney injury (AKI) and nephron loss in intensive care unit patients to improve the AKI-to-chronic kidney disease (CKD) progression. d Ferroptosis inhibition as an add on treatment option to anti-tuberculosis antibiotic therapy in critically ill patients may improve respiratory outcomes and limit long-term complications following tuberculosis infection.

Another example of iatrogenic ferroptosis induction is ischemia-reperfusion injury as a consequence of cardiac surgery (Fig. 4b). Upon clinical trial conditions, ferrostatins can be applied before the onset of surgery which precedes the onset of ferroptosis upon reperfusion by as many hours as the surgical procedure may take. As many cardiac patients exhibit compromised renal function, the inclusion of patients with an eGFR or 20 ml/min/1.73 m² in a previous study may also be helpful [59] in the design for this trial, as the common exclusion criterion of an eGFR >30 ml/min/1.73 m² should not apply. This allows to employ the eGFR slope, e.g., assessed over an episode of 6 weeks, alongside with the diagnosis of end stage renal disease (ESRD) and the need for dialysis as secondary and primary endpoints, respectively.

Acute kidney injury is amongst the best studied conditions in ferroptosis research. However, AKI on intensive care units is pathophysiologically different from experimental IRI [121] in its nature as it represents a progressive disease in which nephron by nephron may undergo synchronized regulated necrosis by ferroptosis over a period of several days or weeks [122]. It is an option to treat freshly resuscitated individuals with ferrostatins and enroll them into a clinical trial as soon as they enter the emergency room on an ICU (Fig. 4c). Ferrostatins could be applied in the potentially intubated patients intravenously for a defined period of days (e.g., 5 days) until blood pressure can be sufficiently controlled the situation of cardiovascular shock can be overcome. Primary and secondary endpoints could be defined as composite of death by any cause and requirement for renal replacement therapy (RRT). Alternatively, if no RRT is required, simple serum concentrations of urea and creatinine alongside the estimated glomerular filtration rate (eGFR) could serve as readout systems e.g., 7 or 10 days after discharge from the ICU and 6 months following the enrollment into the trial.

Finally, ferroptosis induction is a pathogenic factor to bacteria [123–125]. One of the most prominent examples causing global disease burden is mycobacterium tuberculosis [55]. During granuloma formation and tissue necrosis upon tuberculosis infection of the lungs, ferrostatins might oppose a bacterial virulence factor [125]. In such conditions, ferrostatins would have to be applied for several weeks to potentially unfold their beneficial effects (Fig. 4d). However, upon severe infection, this condition requires weeks of antibiotic treatment in the hospital in almost all cases, since only intravenous antibiotics are available. During such conditions, the enrollment of critically infected patients appears manageable to test the contribution of ferroptotic tissue damage to the overall disease progression.

Outlook

Advancing therapies to create novel first-in-class drugs for clinical routine requires sequences of mechanistic basic research, biomedical research, translational preclinical research and state-of-the-art drug design. It further requires the definition of clear endpoint studies once the disease patterns are sufficiently understood, and it involves the careful assessment of side effect profiles, especially when novel therapeutic routes are tested in humans. If the clinical readout systems are unequivocally defined, does advancing therapies require a specific biomarker for a sematic term such as “ferroptosis”, or is it sufficient to improve the outcome directly? In our opinion, it is the latter.

For decades, antioxidant treatments have been considered without a clear endpoint to test. “Non-specificity” was a principle of such approaches. Amongst stakeholders in the pharmaceutical industry, this has supported the preconception that radical trapping antioxidants (lipophilic or not), in contrast to kinase inhibitors or monoclonal antibodies, cannot be modern drugs and would be too “unconventional”. A similar preconception was associated with mRNA-based vaccines until the pandemic thought us differently. In our opinion, we should let the ongoing cardiovascular pandemic stimulate our courage to test “unconventional” approaches. Along the same line, the ongoing M. tuberculosis pandemic is another paramount reason to take courage for advanced anti-ferroptosis treatments.

Acknowledgements

We thank all members of the Linkermann lab for continuous discussions.

Author contributions

FM wrote the manuscript and prepared the figures. WT, SG, SB, AS and MG helped conceptualizing the manuscript. AL designed the figures, conceptualized, wrote and revised the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Vitale I Pietrocola F Guilbaud E Aaronson SA Abrams JM Adam D Apoptotic cell death in disease—current understanding of the NCCD 2023 Cell Death Differ 2023 30 1097 154 10.1038/s41418-023-01153-w 37100955
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease—current understanding of the NCCD 2023. Cell Death Differ. 2023;30:1097–154.37100955 10.1038/s41418-023-01153-w
2. Linkermann A Green DR Necroptosis N Engl J Med 2014 370 455 65 10.1056/NEJMra1310050 24476434
Linkermann A, Green DR. Necroptosis. N Engl J Med. 2014;370:455–65.24476434 10.1056/NEJMra1310050
3. Newton K Strasser A Kayagaki N Dixit VM Cell death Cell 2024 187 235 56 10.1016/j.cell.2023.11.044 38242081
Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187:235–56.38242081 10.1016/j.cell.2023.11.044
4. Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25:424–42.
5. Veeckmans G, Van San E, Vanden Berghe T. A guide to ferroptosis, the biological rust of cellular membranes. FEBS J. 2023;291:2767–83.
6. Jiang X Stockwell BR Conrad M Ferroptosis: mechanisms, biology and role in disease Nat Rev Mol Cell Biol 2021 22 266 82 10.1038/s41580-020-00324-8 33495651
Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266–82.33495651 10.1038/s41580-020-00324-8
7. Galluzzi L Bravo-San Pedro JM Vitale I Aaronson SA Abrams JM Adam D Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 Cell Death Differ 2015 22 58 73 10.1038/cdd.2014.137 25236395
Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ. 2015;22:58–73.25236395 10.1038/cdd.2014.137
8. Degen M Santos JC Pluhackova K Cebrero G Ramos S Jankevicius G Structural basis of NINJ1-mediated plasma membrane rupture in cell death Nature 2023 618 1065 71 10.1038/s41586-023-05991-z 37198476
Degen M, Santos JC, Pluhackova K, Cebrero G, Ramos S, Jankevicius G, et al. Structural basis of NINJ1-mediated plasma membrane rupture in cell death. Nature. 2023;618:1065–71.37198476 10.1038/s41586-023-05991-z
9. Kayagaki N Stowe IB Alegre K Deshpande I Wu S Lin Z Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury Nature 2023 618 1072 7 10.1038/s41586-023-06191-5 37196676
Kayagaki N, Stowe IB, Alegre K, Deshpande I, Wu S, Lin Z, et al. Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury. Nature. 2023;618:1072–7.37196676 10.1038/s41586-023-06191-5
10. Ramos S Hartenian E Santos JC Walch P Broz P NINJ1 induces plasma membrane rupture and release of damage-associated molecular pattern molecules during ferroptosis EMBO J 2024 43 1164 86 10.1038/s44318-024-00055-y 38396301
Ramos S, Hartenian E, Santos JC, Walch P, Broz P. NINJ1 induces plasma membrane rupture and release of damage-associated molecular pattern molecules during ferroptosis. EMBO J. 2024;43:1164–86.38396301 10.1038/s44318-024-00055-y
11. Krysko DV Garg AD Kaczmarek A Krysko O Agostinis P Vandenabeele P Immunogenic cell death and DAMPs in cancer therapy Nat Rev Cancer 2012 12 860 75 10.1038/nrc3380 23151605
Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–75.23151605 10.1038/nrc3380
12. Land WG Agostinis P Gasser S Garg AD Linkermann A Transplantation and damage-associated molecular patterns (DAMPs) Am J Transplant 2016 16 3338 61 10.1111/ajt.13963 27421829
Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and damage-associated molecular patterns (DAMPs). Am J Transplant. 2016;16:3338–61.27421829 10.1111/ajt.13963
13. Land WG Agostinis P Gasser S Garg AD Linkermann A DAMP-induced allograft and tumor rejection: the circle is closing Am J Transplant 2016 16 3322 37 10.1111/ajt.14012 27529775
Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. DAMP-induced allograft and tumor rejection: the circle is closing. Am J Transplant. 2016;16:3322–37.27529775 10.1111/ajt.14012
14. Sarhan M Land WG Tonnus W Hugo CP Linkermann A Origin and consequences of necroinflammation Physiol Rev 2018 98 727 80 10.1152/physrev.00041.2016 29465288
Sarhan M, Land WG, Tonnus W, Hugo CP, Linkermann A. Origin and consequences of necroinflammation. Physiol Rev. 2018;98:727–80.29465288 10.1152/physrev.00041.2016
15. von Massenhausen A Tonnus W Linkermann A Cell death pathways drive necroinflammation during acute kidney injury Nephron 2018 140 144 7 10.1159/000490807 29961062
von Massenhausen A, Tonnus W, Linkermann A. Cell death pathways drive necroinflammation during acute kidney injury. Nephron. 2018;140:144–7.29961062 10.1159/000490807
16. Greenhill C Dexamethasone in patients with diabetes mellitus Nat Rev Endocrinol 2022 18 333 35414024
Greenhill C. Dexamethasone in patients with diabetes mellitus. Nat Rev Endocrinol. 2022;18:333.35414024
17. von Mässenhausen A Zamora Gonzalez N Maremonti F Belavgeni A Tonnus W Meyer C Dexamethasone sensitizes to ferroptosis by glucocorticoid receptor-induced dipeptidase-1 expression and glutathione depletion Sci Adv 2022 8 eabl8920 10.1126/sciadv.abl8920 35108055
von Mässenhausen A, Zamora Gonzalez N, Maremonti F, Belavgeni A, Tonnus W, Meyer C, et al. Dexamethasone sensitizes to ferroptosis by glucocorticoid receptor-induced dipeptidase-1 expression and glutathione depletion. Sci Adv. 2022;8:eabl8920.35108055 10.1126/sciadv.abl8920
18. Freitas FP, Alborzinia H, Dos Santos AF, Nepachalovich P, Pedrera L, Zilka O, et al. 7-Dehydrocholesterol is an endogenous suppressor of ferroptosis. Nature. 2024;626:401–10.
19. Li Y Ran Q Duan Q Jin J Wang Y Yu L 7-Dehydrocholesterol dictates ferroptosis sensitivity Nature 2024 626 411 8 10.1038/s41586-023-06983-9 38297130
Li Y, Ran Q, Duan Q, Jin J, Wang Y, Yu L, et al. 7-Dehydrocholesterol dictates ferroptosis sensitivity. Nature. 2024;626:411–8.38297130 10.1038/s41586-023-06983-9
20. Tonnus W Belavgeni A Beuschlein F Eisenhofer G Fassnacht M Kroiss M The role of regulated necrosis in endocrine diseases Nat Rev Endocrinol 2021 17 497 510 10.1038/s41574-021-00499-w 34135504
Tonnus W, Belavgeni A, Beuschlein F, Eisenhofer G, Fassnacht M, Kroiss M, et al. The role of regulated necrosis in endocrine diseases. Nat Rev Endocrinol. 2021;17:497–510.34135504 10.1038/s41574-021-00499-w
21. Kristensen SL Rørth R Jhund PS Docherty KF Sattar N Preiss D Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet Diabetes Endocrinol 2019 7 776 85 10.1016/S2213-8587(19)30249-9 31422062
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776–85.31422062 10.1016/S2213-8587(19)30249-9
22. Bayır H Dixon SJ Tyurina YY Kellum JA Kagan VE Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney Nat Rev Nephrol 2023 19 315 36 10.1038/s41581-023-00689-x 36922653
Bayır H, Dixon SJ, Tyurina YY, Kellum JA, Kagan VE. Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney. Nat Rev Nephrol. 2023;19:315–36.36922653 10.1038/s41581-023-00689-x
23. Bertero E Maack C Ins and outs of glutathione in cardiac ischemia/reperfusion injury Circ Res 2023 133 877 9 10.1161/CIRCRESAHA.123.323715 37883592
Bertero E, Maack C. Ins and outs of glutathione in cardiac ischemia/reperfusion injury. Circ Res. 2023;133:877–9.37883592 10.1161/CIRCRESAHA.123.323715
24. Maslov LN Popov SV Mukhomedzyanov AV Naryzhnaya NV Voronkov NS Ryabov VV Reperfusion cardiac injury: receptors and the signaling mechanisms Curr Cardiol Rev 2022 18 63 79 10.2174/1573403X18666220413121730 35422224
Maslov LN, Popov SV, Mukhomedzyanov AV, Naryzhnaya NV, Voronkov NS, Ryabov VV, et al. Reperfusion cardiac injury: receptors and the signaling mechanisms. Curr Cardiol Rev. 2022;18:63–79.35422224 10.2174/1573403X18666220413121730
25. Rokop ZP Zhang W Ghosh N Biswas N Das A Lin J Exacerbated ischemia-reperfusion injury in fatty livers is mediated by lipid peroxidation stress and ferroptosis Surgery 2024 175 1539 46 10.1016/j.surg.2024.02.001 38508920
Rokop ZP, Zhang W, Ghosh N, Biswas N, Das A, Lin J, et al. Exacerbated ischemia-reperfusion injury in fatty livers is mediated by lipid peroxidation stress and ferroptosis. Surgery. 2024;175:1539–46.38508920 10.1016/j.surg.2024.02.001
26. Yamada N Karasawa T Wakiya T Sadatomo A Ito H Kamata R Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: potential role of ferroptosis Am J Transplant 2020 20 1606 18 10.1111/ajt.15773 31909544
Yamada N, Karasawa T, Wakiya T, Sadatomo A, Ito H, Kamata R, et al. Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: potential role of ferroptosis. Am J Transplant. 2020;20:1606–18.31909544 10.1111/ajt.15773
27. Linkermann A Skouta R Himmerkus N Mulay SR Dewitz C De Zen F Synchronized renal tubular cell death involves ferroptosis Proc Natl Acad Sci USA 2014 111 16836 41 10.1073/pnas.1415518111 25385600
Linkermann A, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci USA 2014;111:16836–41.25385600 10.1073/pnas.1415518111
28. Tonnus W Meyer C Steinebach C Belavgeni A von Mässenhausen A Gonzalez NZ Dysfunction of the key ferroptosis-surveilling systems hypersensitizes mice to tubular necrosis during acute kidney injury Nat Commun 2021 12 4402 10.1038/s41467-021-24712-6 34285231
Tonnus W, Meyer C, Steinebach C, Belavgeni A, von Mässenhausen A, Gonzalez NZ, et al. Dysfunction of the key ferroptosis-surveilling systems hypersensitizes mice to tubular necrosis during acute kidney injury. Nat Commun. 2021;12:4402.34285231 10.1038/s41467-021-24712-6
29. Vanden Berghe T Linkermann A Jouan-Lanhouet S Walczak H Vandenabeele P Regulated necrosis: the expanding network of non-apoptotic cell death pathways Nat Rev Mol Cell Biol 2014 15 135 47 10.1038/nrm3737 24452471
Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 2014;15:135–47.24452471 10.1038/nrm3737
30. Mata-Pérez C Spoel SH Thioredoxin-mediated redox signalling in plant immunity Plant Sci 2019 279 27 33 10.1016/j.plantsci.2018.05.001 30709489
Mata-Pérez C, Spoel SH. Thioredoxin-mediated redox signalling in plant immunity. Plant Sci. 2019;279:27–33.30709489 10.1016/j.plantsci.2018.05.001
31. Kar A Paramasivam B Jayakumar D Swaroop AK Jubie S Thioredoxin interacting protein inhibitors in diabetes mellitus: a critical review Curr Drug Res Rev 2023 15 228 40 10.2174/2589977515666230214101808 36786139
Kar A, Paramasivam B, Jayakumar D, Swaroop AK, Jubie S. Thioredoxin interacting protein inhibitors in diabetes mellitus: a critical review. Curr Drug Res Rev. 2023;15:228–40.36786139 10.2174/2589977515666230214101808
32. Masutani H Thioredoxin-interacting protein in cancer and diabetes Antioxid Redox Signal 2022 36 1001 22 10.1089/ars.2021.0038 34384271
Masutani H. Thioredoxin-interacting protein in cancer and diabetes. Antioxid Redox Signal. 2022;36:1001–22.34384271 10.1089/ars.2021.0038
33. Conrad M Pratt DA The chemical basis of ferroptosis Nat Chem Biol 2019 15 1137 47 10.1038/s41589-019-0408-1 31740834
Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol. 2019;15:1137–47.31740834 10.1038/s41589-019-0408-1
34. Friedmann Angeli JP Schneider M Proneth B Tyurina YY Tyurin VA Hammond VJ Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice Nat Cell Biol 2014 16 1180 91 10.1038/ncb3064 25402683
Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180–91.25402683 10.1038/ncb3064
35. Ingold I, Berndt C, Schmitt S, Doll S, Poschmann G, Buday K, et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis. Cell. 2017;172:409–422.e21.
36. Bersuker K Hendricks J Li Z Magtanong L Ford B Tang PH The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis Nature 2019 575 688 92 10.1038/s41586-019-1705-2 31634900
Bersuker K, Hendricks J, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575:688–92.31634900 10.1038/s41586-019-1705-2
37. Doll S Freitas FP Shah R Aldrovandi M da Silva MC Ingold I FSP1 is a glutathione-independent ferroptosis suppressor Nature 2019 575 693 8 10.1038/s41586-019-1707-0 31634899
Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693–8.31634899 10.1038/s41586-019-1707-0
38. Liang D Feng Y Zandkarimi F Wang H Zhang Z Kim J Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones Cell 2023 186 2748 64.e22 10.1016/j.cell.2023.05.003 37267948
Liang D, Feng Y, Zandkarimi F, Wang H, Zhang Z, Kim J, et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell. 2023;186:2748–64.e22.37267948 10.1016/j.cell.2023.05.003
39. Hirata Y Cai R Volchuk A Steinberg BE Saito Y Matsuzawa A Lipid peroxidation increases membrane tension, Piezo1 gating, and cation permeability to execute ferroptosis Curr Biol 2023 33 1282 94.e5 10.1016/j.cub.2023.02.060 36898371
Hirata Y, Cai R, Volchuk A, Steinberg BE, Saito Y, Matsuzawa A, et al. Lipid peroxidation increases membrane tension, Piezo1 gating, and cation permeability to execute ferroptosis. Curr Biol. 2023;33:1282–94.e5.36898371 10.1016/j.cub.2023.02.060
40. David L Borges JP Hollingsworth LR Volchuk A Jansen I Garlick E NINJ1 mediates plasma membrane rupture by cutting and releasing membrane disks Cell 2024 187 2224 35.e16 10.1016/j.cell.2024.03.008 38614101
David L, Borges JP, Hollingsworth LR, Volchuk A, Jansen I, Garlick E, et al. NINJ1 mediates plasma membrane rupture by cutting and releasing membrane disks. Cell. 2024;187:2224–35.e16.38614101 10.1016/j.cell.2024.03.008
41. Alim I Caulfield JT Chen Y Swarup V Geschwind DH Ivanova E Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke Cell 2019 177 1262 79.e25 10.1016/j.cell.2019.03.032 31056284
Alim I, Caulfield JT, Chen Y, Swarup V, Geschwind DH, Ivanova E, et al. Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke. Cell. 2019;177:1262–79.e25.31056284 10.1016/j.cell.2019.03.032
42. Shah AM Giacca M Small non-coding RNA therapeutics for cardiovascular disease Eur Heart J 2022 43 4548 61 10.1093/eurheartj/ehac463 36106499
Shah AM, Giacca M. Small non-coding RNA therapeutics for cardiovascular disease. Eur Heart J. 2022;43:4548–61.36106499 10.1093/eurheartj/ehac463
43. von Mässenhausen A Schlecht MN Beer K Maremonti F Tonnus W Belavgeni A Treatment with siRNAs is commonly associated with GPX4 up-regulation and target knockdown-independent sensitization to ferroptosis Sci Adv 2024 10 eadk7329 10.1126/sciadv.adk7329 38489367
von Mässenhausen A, Schlecht MN, Beer K, Maremonti F, Tonnus W, Belavgeni A, et al. Treatment with siRNAs is commonly associated with GPX4 up-regulation and target knockdown-independent sensitization to ferroptosis. Sci Adv. 2024;10:eadk7329.38489367 10.1126/sciadv.adk7329
44. Dolma S Lessnick SL Hahn WC Stockwell BR Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells Cancer Cell 2003 3 285 96 10.1016/S1535-6108(03)00050-3 12676586
Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell. 2003;3:285–96.12676586 10.1016/S1535-6108(03)00050-3
45. Dixon SJ Lemberg KM Lamprecht MR Skouta R Zaitsev EM Gleason CE Ferroptosis: an iron-dependent form of nonapoptotic cell death Cell 2012 149 1060 72 10.1016/j.cell.2012.03.042 22632970
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060–72.22632970 10.1016/j.cell.2012.03.042
46. Doll S Conrad M Iron and ferroptosis: a still ill-defined liaison IUBMB Life 2017 69 423 34 10.1002/iub.1616 28276141
Doll S, Conrad M. Iron and ferroptosis: a still ill-defined liaison. IUBMB Life. 2017;69:423–34.28276141 10.1002/iub.1616
47. Jia H Liu X Cao Y Niu H Lan Z Li R Deferoxamine ameliorates neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury Brain Res 2023 1812 148383 10.1016/j.brainres.2023.148383 37149247
Jia H, Liu X, Cao Y, Niu H, Lan Z, Li R, et al. Deferoxamine ameliorates neurological dysfunction by inhibiting ferroptosis and neuroinflammation after traumatic brain injury. Brain Res. 2023;1812:148383.37149247 10.1016/j.brainres.2023.148383
48. Fraga CM Tomasi CD Biff D Topanotti MF Felisberto F Vuolo F The effects of N-acetylcysteine and deferoxamine on plasma cytokine and oxidative damage parameters in critically ill patients with prolonged hypotension: a randomized controlled trial J Clin Pharm 2012 52 1365 72 10.1177/0091270011418657
Fraga CM, Tomasi CD, Biff D, Topanotti MF, Felisberto F, Vuolo F, et al. The effects of N-acetylcysteine and deferoxamine on plasma cytokine and oxidative damage parameters in critically ill patients with prolonged hypotension: a randomized controlled trial. J Clin Pharm. 2012;52:1365–72.10.1177/0091270011418657
49. Fraga CM Tomasi CD Damasio DC Vuolo F Ritter C Dal-Pizzol F N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial Crit Care 2016 20 331 10.1186/s13054-016-1504-1 27745551
Fraga CM, Tomasi CD, Damasio DC, Vuolo F, Ritter C, Dal-Pizzol F. N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial. Crit Care. 2016;20:331.27745551 10.1186/s13054-016-1504-1
50. Barayeu U Schilling D Eid M Xavier da Silva TN Schlicker L Mitreska N Hydropersulfides inhibit lipid peroxidation and ferroptosis by scavenging radicals Nat Chem Biol 2023 19 28 37 10.1038/s41589-022-01145-w 36109647
Barayeu U, Schilling D, Eid M, Xavier da Silva TN, Schlicker L, Mitreska N, et al. Hydropersulfides inhibit lipid peroxidation and ferroptosis by scavenging radicals. Nat Chem Biol. 2023;19:28–37.36109647 10.1038/s41589-022-01145-w
51. Zeitler L Fiore A Meyer C Russier M Zanella G Suppmann S Anti-ferroptotic mechanism of IL4i1-mediated amino acid metabolism eLife 2021 10 e64806 10.7554/eLife.64806 33646117
Zeitler L, Fiore A, Meyer C, Russier M, Zanella G, Suppmann S, et al. Anti-ferroptotic mechanism of IL4i1-mediated amino acid metabolism. eLife. 2021;10:e64806.33646117 10.7554/eLife.64806
52. Zeitler L Murray PJ IL4i1 and IDO1: oxidases that control a tryptophan metabolic nexus in cancer J Biol Chem 2023 299 104827 10.1016/j.jbc.2023.104827 37196768
Zeitler L, Murray PJ. IL4i1 and IDO1: oxidases that control a tryptophan metabolic nexus in cancer. J Biol Chem. 2023;299:104827.37196768 10.1016/j.jbc.2023.104827
53. Van Coillie S Van San E Goetschalckx I Wiernicki B Mukhopadhyay B Tonnus W Targeting ferroptosis protects against experimental (multi)organ dysfunction and death Nat Commun 2022 13 1046 10.1038/s41467-022-28718-6 35210435
Van Coillie S, Van San E, Goetschalckx I, Wiernicki B, Mukhopadhyay B, Tonnus W, et al. Targeting ferroptosis protects against experimental (multi)organ dysfunction and death. Nat Commun. 2022;13:1046.35210435 10.1038/s41467-022-28718-6
54. Mishima E, Sato E, Ito J, Yamada KI, Suzuki C, Oikawa Y, et al. Drugs repurposed as antiferroptosis agents suppress organ damage, including AKI, by functioning as lipid peroxyl radical scavengers. J Am Soc Nephrol. 2019;31:280–96.
55. Menzies NA Allwood BW Dean AS Dodd PJ Houben R James LP Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis Nat Commun 2023 14 6182 10.1038/s41467-023-41937-9 37794037
Menzies NA, Allwood BW, Dean AS, Dodd PJ, Houben R, James LP, et al. Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis. Nat Commun. 2023;14:6182.37794037 10.1038/s41467-023-41937-9
56. Kagan VE Mao G Qu F Angeli JP Doll S Croix CS Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis Nat Chem Biol 2017 13 81 90 10.1038/nchembio.2238 27842066
Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81–90.27842066 10.1038/nchembio.2238
57. Mishima E Ito J Wu Z Nakamura T Wahida A Doll S A non-canonical vitamin K cycle is a potent ferroptosis suppressor Nature 2022 608 778 83 10.1038/s41586-022-05022-3 35922516
Mishima E, Ito J, Wu Z, Nakamura T, Wahida A, Doll S, et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature. 2022;608:778–83.35922516 10.1038/s41586-022-05022-3
58. Sanyal AJ Chalasani N Kowdley KV McCullough A Diehl AM Bass NM Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 2010 362 1675 85 10.1056/NEJMoa0907929 20427778
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.20427778 10.1056/NEJMoa0907929
59. Eelderink C Kremer D Riphagen IJ Knobbe TJ Schurgers LJ Pasch A Effect of vitamin K supplementation on serum calcification propensity and arterial stiffness in vitamin K-deficient kidney transplant recipients: a double-blind, randomized, placebo-controlled clinical trial Am J Transplant 2023 23 520 30 10.1016/j.ajt.2022.12.015 36695702
Eelderink C, Kremer D, Riphagen IJ, Knobbe TJ, Schurgers LJ, Pasch A, et al. Effect of vitamin K supplementation on serum calcification propensity and arterial stiffness in vitamin K-deficient kidney transplant recipients: a double-blind, randomized, placebo-controlled clinical trial. Am J Transplant. 2023;23:520–30.36695702 10.1016/j.ajt.2022.12.015
60. Ai Y Meng Y Yan B Zhou Q Wang X The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death Mol Cell 2024 84 170 9 10.1016/j.molcel.2023.11.040 38181758
Ai Y, Meng Y, Yan B, Zhou Q, Wang X. The biochemical pathways of apoptotic, necroptotic, pyroptotic, and ferroptotic cell death. Mol Cell. 2024;84:170–9.38181758 10.1016/j.molcel.2023.11.040
61. Sogabe K Roeser NF Venkatachalam MA Weinberg JM Differential cytoprotection by glycine against oxidant damage to proximal tubule cells Kidney Int 1996 50 845 54 10.1038/ki.1996.384 8872959
Sogabe K, Roeser NF, Venkatachalam MA, Weinberg JM. Differential cytoprotection by glycine against oxidant damage to proximal tubule cells. Kidney Int. 1996;50:845–54.8872959 10.1038/ki.1996.384
62. Weinberg JM Roeser NF Davis JA Venkatachalam MA Glycine-protected, hypoxic, proximal tubules develop severely compromised energetic function Kidney Int 1997 52 140 51 10.1038/ki.1997.313 9211356
Weinberg JM, Roeser NF, Davis JA, Venkatachalam MA. Glycine-protected, hypoxic, proximal tubules develop severely compromised energetic function. Kidney Int. 1997;52:140–51.9211356 10.1038/ki.1997.313
63. Skouta R Dixon SJ Wang J Dunn DE Orman M Shimada K Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models J Am Chem Soc 2014 136 4551 6 10.1021/ja411006a 24592866
Skouta R, Dixon SJ, Wang J, Dunn DE, Orman M, Shimada K, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc. 2014;136:4551–6.24592866 10.1021/ja411006a
64. Borges JP Sætra RSR Volchuk A Bugge M Devant P Sporsheim B Glycine inhibits NINJ1 membrane clustering to suppress plasma membrane rupture in cell death eLife 2022 11 e78609 10.7554/eLife.78609 36468682
Borges JP, Sætra RSR, Volchuk A, Bugge M, Devant P, Sporsheim B, et al. Glycine inhibits NINJ1 membrane clustering to suppress plasma membrane rupture in cell death. eLife. 2022;11:e78609.36468682 10.7554/eLife.78609
65. Lau A Rahn JJ Chappellaz M Chung H Benediktsson H Bihan D Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury Sci Adv 2022 8 eabm0142 10.1126/sciadv.abm0142 35108057
Lau A, Rahn JJ, Chappellaz M, Chung H, Benediktsson H, Bihan D, et al. Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury. Sci Adv. 2022;8:eabm0142.35108057 10.1126/sciadv.abm0142
66. Alshaer W Zureigat H Al Karaki A Al-Kadash A Gharaibeh L Hatmal MM siRNA: mechanism of action, challenges, and therapeutic approaches Eur J Pharmacol 2021 905 174178 10.1016/j.ejphar.2021.174178 34044011
Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal MM, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905:174178.34044011 10.1016/j.ejphar.2021.174178
67. Wu B Hur S How RIG-I like receptors activate MAVS Curr Opin Virol 2015 12 91 8 10.1016/j.coviro.2015.04.004 25942693
Wu B, Hur S. How RIG-I like receptors activate MAVS. Curr Opin Virol. 2015;12:91–8.25942693 10.1016/j.coviro.2015.04.004
68. Rodencal J Kim N He A Li VL Lange M He J Sensitization of cancer cells to ferroptosis coincident with cell cycle arrest Cell Chem Biol 2024 31 234 48.e13 10.1016/j.chembiol.2023.10.011 37963466
Rodencal J, Kim N, He A, Li VL, Lange M, He J, et al. Sensitization of cancer cells to ferroptosis coincident with cell cycle arrest. Cell Chem Biol. 2024;31:234–48.e13.37963466 10.1016/j.chembiol.2023.10.011
69. Puente BN Kimura W Muralidhar SA Moon J Amatruda JF Phelps KL The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response Cell 2014 157 565 79 10.1016/j.cell.2014.03.032 24766806
Puente BN, Kimura W, Muralidhar SA, Moon J, Amatruda JF, Phelps KL, et al. The oxygen-rich postnatal environment induces cardiomyocyte cell-cycle arrest through DNA damage response. Cell. 2014;157:565–79.24766806 10.1016/j.cell.2014.03.032
70. Antoszczak M Müller S Cañeque T Colombeau L Dusetti N Santofimia-Castaño P Iron-sensitive prodrugs that trigger active ferroptosis in drug-tolerant pancreatic cancer cells J Am Chem Soc 2022 144 11536 45 10.1021/jacs.2c03973 35696539
Antoszczak M, Müller S, Cañeque T, Colombeau L, Dusetti N, Santofimia-Castaño P, et al. Iron-sensitive prodrugs that trigger active ferroptosis in drug-tolerant pancreatic cancer cells. J Am Chem Soc. 2022;144:11536–45.35696539 10.1021/jacs.2c03973
71. Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547:453–7.
72. Rodriguez R Schreiber SL Conrad M Persister cancer cells: iron addiction and vulnerability to ferroptosis Mol Cell 2022 82 728 40 10.1016/j.molcel.2021.12.001 34965379
Rodriguez R, Schreiber SL, Conrad M. Persister cancer cells: iron addiction and vulnerability to ferroptosis. Mol Cell. 2022;82:728–40.34965379 10.1016/j.molcel.2021.12.001
73. Del Re DP Amgalan D Linkermann A Liu Q Kitsis RN Fundamental mechanisms of regulated cell death and implications for heart disease Physiol Rev 2019 99 1765 817 10.1152/physrev.00022.2018 31364924
Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 2019;99:1765–817.31364924 10.1152/physrev.00022.2018
74. Li W, Feng G, Gauthier JM, Lokshina I, Higashikubo R, Evans S, et al. Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation. J Clin Invest. 2019;129:2293–2304.
75. Fang X Cai Z Wang H Han D Cheng Q Zhang P Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-Mediated Ferroptosis Circ Res 2020 127 486 501 10.1161/CIRCRESAHA.120.316509 32349646
Fang X, Cai Z, Wang H, Han D, Cheng Q, Zhang P, et al. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-Mediated Ferroptosis. Circ Res. 2020;127:486–501.32349646 10.1161/CIRCRESAHA.120.316509
76. Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci. 2019;116:2672–80.
77. Chu LK Cao X Wan L Diao Q Zhu Y Kan Y Autophagy of OTUD5 destabilizes GPX4 to confer ferroptosis-dependent kidney injury Nat Commun 2023 14 8393 10.1038/s41467-023-44228-5 38110369
Chu LK, Cao X, Wan L, Diao Q, Zhu Y, Kan Y, et al. Autophagy of OTUD5 destabilizes GPX4 to confer ferroptosis-dependent kidney injury. Nat Commun. 2023;14:8393.38110369 10.1038/s41467-023-44228-5
78. Su L Jiang X Yang C Zhang J Chen B Li Y Pannexin 1 mediates ferroptosis that contributes to renal ischemia/reperfusion injury J Biol Chem 2019 294 19395 404 10.1074/jbc.RA119.010949 31694915
Su L, Jiang X, Yang C, Zhang J, Chen B, Li Y, et al. Pannexin 1 mediates ferroptosis that contributes to renal ischemia/reperfusion injury. J Biol Chem. 2019;294:19395–404.31694915 10.1074/jbc.RA119.010949
79. Zhao Z Wu J Xu H Zhou C Han B Zhu H XJB-5-131 inhibited ferroptosis in tubular epithelial cells after ischemia-reperfusion injury Cell Death Dis 2020 11 629 10.1038/s41419-020-02871-6 32796819
Zhao Z, Wu J, Xu H, Zhou C, Han B, Zhu H, et al. XJB-5-131 inhibited ferroptosis in tubular epithelial cells after ischemia-reperfusion injury. Cell Death Dis. 2020;11:629.32796819 10.1038/s41419-020-02871-6
80. Guo J Song Z Yu J Li C Jin C Duan W Hepatocyte-specific TMEM16A deficiency alleviates hepatic ischemia/reperfusion injury via suppressing GPX4-mediated ferroptosis Cell Death Dis 2022 13 1072 10.1038/s41419-022-05518-w 36572666
Guo J, Song Z, Yu J, Li C, Jin C, Duan W, et al. Hepatocyte-specific TMEM16A deficiency alleviates hepatic ischemia/reperfusion injury via suppressing GPX4-mediated ferroptosis. Cell Death Dis. 2022;13:1072.36572666 10.1038/s41419-022-05518-w
81. Wang F Liu X Huang F Zhou Y Wang X Song Z Gut microbiota-derived gamma-aminobutyric acid from metformin treatment reduces hepatic ischemia/reperfusion injury through inhibiting ferroptosis eLife 2024 12 RP89045 10.7554/eLife.89045.4 38488837
Wang F, Liu X, Huang F, Zhou Y, Wang X, Song Z, et al. Gut microbiota-derived gamma-aminobutyric acid from metformin treatment reduces hepatic ischemia/reperfusion injury through inhibiting ferroptosis. eLife. 2024;12:RP89045.38488837 10.7554/eLife.89045.4
82. Wu Y Jiao H Yue Y He K Jin Y Zhang J Ubiquitin ligase E3 HUWE1/MULE targets transferrin receptor for degradation and suppresses ferroptosis in acute liver injury Cell Death Differ 2022 29 1705 18 10.1038/s41418-022-00957-6 35260822
Wu Y, Jiao H, Yue Y, He K, Jin Y, Zhang J, et al. Ubiquitin ligase E3 HUWE1/MULE targets transferrin receptor for degradation and suppresses ferroptosis in acute liver injury. Cell Death Differ. 2022;29:1705–18.35260822 10.1038/s41418-022-00957-6
83. Yamada N Karasawa T Ito J Yamamuro D Morimoto K Nakamura T Inhibition of 7-dehydrocholesterol reductase prevents hepatic ferroptosis under an active state of sterol synthesis Nat Commun 2024 15 2195 10.1038/s41467-024-46386-6 38472233
Yamada N, Karasawa T, Ito J, Yamamuro D, Morimoto K, Nakamura T, et al. Inhibition of 7-dehydrocholesterol reductase prevents hepatic ferroptosis under an active state of sterol synthesis. Nat Commun. 2024;15:2195.38472233 10.1038/s41467-024-46386-6
84. Li T Zhao L Li Y Dang M Lu J Lu Z PPM1K mediates metabolic disorder of branched-chain amino acid and regulates cerebral ischemia-reperfusion injury by activating ferroptosis in neurons Cell Death Dis 2023 14 634 10.1038/s41419-023-06135-x 37752100
Li T, Zhao L, Li Y, Dang M, Lu J, Lu Z, et al. PPM1K mediates metabolic disorder of branched-chain amino acid and regulates cerebral ischemia-reperfusion injury by activating ferroptosis in neurons. Cell Death Dis. 2023;14:634.37752100 10.1038/s41419-023-06135-x
85. Wang F Ma M Yang J Shi X Wang J Xu Z Neuroprotective effects of activin A against cerebral ischemia/reperfusion injury in mice by enhancing Nrf2 expression to attenuate neuronal ferroptosis ACS Chem Neurosci 2023 14 2818 26 10.1021/acschemneuro.3c00374 37473431
Wang F, Ma M, Yang J, Shi X, Wang J, Xu Z. Neuroprotective effects of activin A against cerebral ischemia/reperfusion injury in mice by enhancing Nrf2 expression to attenuate neuronal ferroptosis. ACS Chem Neurosci. 2023;14:2818–26.37473431 10.1021/acschemneuro.3c00374
86. Xu Y Li K Zhao Y Zhou L Liu Y Zhao J Role of ferroptosis in stroke Cell Mol Neurobiol 2023 43 205 22 10.1007/s10571-022-01196-6 35102454
Xu Y, Li K, Zhao Y, Zhou L, Liu Y, Zhao J. Role of ferroptosis in stroke. Cell Mol Neurobiol. 2023;43:205–22.35102454 10.1007/s10571-022-01196-6
87. Zhang T Yang M Ma C Wei X Zhang Z BACH1 encourages ferroptosis by activating KDM4C-mediated COX2 demethylation after cerebral ischemia-reperfusion injury Eur J Neurosci 2023 58 2194 214 10.1111/ejn.16035 37161649
Zhang T, Yang M, Ma C, Wei X, Zhang Z. BACH1 encourages ferroptosis by activating KDM4C-mediated COX2 demethylation after cerebral ischemia-reperfusion injury. Eur J Neurosci. 2023;58:2194–214.37161649 10.1111/ejn.16035
88. Cai W Liu L Shi X Liu Y Wang J Fang X Alox15/15-HpETE aggravates myocardial ischemia-reperfusion injury by promoting cardiomyocyte ferroptosis Circulation 2023 147 1444 60 10.1161/CIRCULATIONAHA.122.060257 36987924
Cai W, Liu L, Shi X, Liu Y, Wang J, Fang X, et al. Alox15/15-HpETE aggravates myocardial ischemia-reperfusion injury by promoting cardiomyocyte ferroptosis. Circulation. 2023;147:1444–60.36987924 10.1161/CIRCULATIONAHA.122.060257
89. Han X Zhang J Liu J Wang H Du F Zeng X Targeting ferroptosis: a novel insight against myocardial infarction and ischemia-reperfusion injuries Apoptosis 2023 28 108 23 10.1007/s10495-022-01785-2 36474078
Han X, Zhang J, Liu J, Wang H, Du F, Zeng X, et al. Targeting ferroptosis: a novel insight against myocardial infarction and ischemia-reperfusion injuries. Apoptosis. 2023;28:108–23.36474078 10.1007/s10495-022-01785-2
90. Li JY Liu SQ Yao RQ Tian YP Yao YM A novel insight into the fate of cardiomyocytes in ischemia-reperfusion injury: from iron metabolism to ferroptosis Front Cell Dev Biol 2021 9 799499 10.3389/fcell.2021.799499 34926476
Li JY, Liu SQ, Yao RQ, Tian YP, Yao YM. A novel insight into the fate of cardiomyocytes in ischemia-reperfusion injury: from iron metabolism to ferroptosis. Front Cell Dev Biol. 2021;9:799499.34926476 10.3389/fcell.2021.799499
91. Li N Jiang W Wang W Xiong R Wu X Geng Q Ferroptosis and its emerging roles in cardiovascular diseases Pharm Res 2021 166 105466 10.1016/j.phrs.2021.105466
Li N, Jiang W, Wang W, Xiong R, Wu X, Geng Q. Ferroptosis and its emerging roles in cardiovascular diseases. Pharm Res. 2021;166:105466.10.1016/j.phrs.2021.105466
92. Miyamoto HD Ikeda M Ide T Tadokoro T Furusawa S Abe K Iron overload via heme degradation in the endoplasmic reticulum triggers ferroptosis in myocardial ischemia-reperfusion injury JACC Basic Transl Sci 2022 7 800 19 10.1016/j.jacbts.2022.03.012 36061338
Miyamoto HD, Ikeda M, Ide T, Tadokoro T, Furusawa S, Abe K, et al. Iron overload via heme degradation in the endoplasmic reticulum triggers ferroptosis in myocardial ischemia-reperfusion injury. JACC Basic Transl Sci. 2022;7:800–19.36061338 10.1016/j.jacbts.2022.03.012
93. Wu X Li Y Zhang S Zhou X Ferroptosis as a novel therapeutic target for cardiovascular disease Theranostics 2021 11 3052 9 10.7150/thno.54113 33537073
Wu X, Li Y, Zhang S, Zhou X. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021;11:3052–9.33537073 10.7150/thno.54113
94. Xiang Q Yi X Zhu XH Wei X Jiang DS Regulated cell death in myocardial ischemia-reperfusion injury Trends Endocrinol Metab 2024 35 219 34 10.1016/j.tem.2023.10.010 37981501
Xiang Q, Yi X, Zhu XH, Wei X, Jiang DS. Regulated cell death in myocardial ischemia-reperfusion injury. Trends Endocrinol Metab. 2024;35:219–34.37981501 10.1016/j.tem.2023.10.010
95. Yang X Kawasaki NK Min J Matsui T Wang F Ferroptosis in heart failure J Mol Cell Cardiol 2022 173 141 53 10.1016/j.yjmcc.2022.10.004 36273661
Yang X, Kawasaki NK, Min J, Matsui T, Wang F. Ferroptosis in heart failure. J Mol Cell Cardiol. 2022;173:141–53.36273661 10.1016/j.yjmcc.2022.10.004
96. Zhang Y Ren X Wang Y Chen D Jiang L Li X Targeting ferroptosis by polydopamine nanoparticles protects heart against ischemia/reperfusion injury ACS Appl Mater Interfaces 2021 13 53671 82 10.1021/acsami.1c18061 34730938
Zhang Y, Ren X, Wang Y, Chen D, Jiang L, Li X, et al. Targeting ferroptosis by polydopamine nanoparticles protects heart against ischemia/reperfusion injury. ACS Appl Mater Interfaces. 2021;13:53671–82.34730938 10.1021/acsami.1c18061
97. Dai C Kong B Qin T Xiao Z Fang J Gong Y Inhibition of ferroptosis reduces susceptibility to frequent excessive alcohol consumption-induced atrial fibrillation Toxicology 2022 465 153055 10.1016/j.tox.2021.153055 34864093
Dai C, Kong B, Qin T, Xiao Z, Fang J, Gong Y, et al. Inhibition of ferroptosis reduces susceptibility to frequent excessive alcohol consumption-induced atrial fibrillation. Toxicology. 2022;465:153055.34864093 10.1016/j.tox.2021.153055
98. Belavgeni A Bornstein SR von Massenhausen A Tonnus W Stumpf J Meyer C Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis Proc Natl Acad Sci USA 2019 116 22269 74 10.1073/pnas.1912700116 31611400
Belavgeni A, Bornstein SR, von Massenhausen A, Tonnus W, Stumpf J, Meyer C, et al. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. Proc Natl Acad Sci USA 2019;116:22269–74.31611400 10.1073/pnas.1912700116
99. Tonnus W, Belavgeni A, Beuschlein F, Eisenhofer G, Fassnacht M, Kroiss M, et al. The role of regulated necrosis in endocrine diseases. Nat. Rev. Endocrinol. 2021;17:497–510.
100. Perakakis N Harb H Hale BG Varga Z Steenblock C Kanczkowski W Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases Lancet Diabetes Endocrinol 2023 11 675 93 10.1016/S2213-8587(23)00154-7 37524103
Perakakis N, Harb H, Hale BG, Varga Z, Steenblock C, Kanczkowski W, et al. Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases. Lancet Diabetes Endocrinol. 2023;11:675–93.37524103 10.1016/S2213-8587(23)00154-7
101. Schepp F Schubert U Schmid J Lehmann S Latunde-Dada GO Kose T Mechanistic insights into ferroptotic cell death in pancreatic islets Horm Metab Res 2024 56 279 85 10.1055/a-2190-2803 37956864
Schepp F, Schubert U, Schmid J, Lehmann S, Latunde-Dada GO, Kose T, et al. Mechanistic insights into ferroptotic cell death in pancreatic islets. Horm Metab Res. 2024;56:279–85.37956864 10.1055/a-2190-2803
102. Steenblock C Richter S Berger I Barovic M Schmid J Schubert U Viral infiltration of pancreatic islets in patients with COVID-19 Nat Commun 2021 12 3534 10.1038/s41467-021-23886-3 34112801
Steenblock C, Richter S, Berger I, Barovic M, Schmid J, Schubert U, et al. Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun. 2021;12:3534.34112801 10.1038/s41467-021-23886-3
103. Zhang QW Wang Y Tong ZY Li CP He LP Vitamin D may play a vital role in alleviating type 2 diabetes mellitus by modulating the ferroptosis signaling pathway Horm Metab Res 2024 56 193 6 10.1055/a-2122-5701 37402397
Zhang QW, Wang Y, Tong ZY, Li CP, He LP. Vitamin D may play a vital role in alleviating type 2 diabetes mellitus by modulating the ferroptosis signaling pathway. Horm Metab Res. 2024;56:193–6.37402397 10.1055/a-2122-5701
104. De Meyer GRY Zurek M Puylaert P Martinet W Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets Nat Rev Cardiol 2024 21 312 25 10.1038/s41569-023-00957-0 38163815
De Meyer GRY, Zurek M, Puylaert P, Martinet W. Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets. Nat Rev Cardiol. 2024;21:312–25.38163815 10.1038/s41569-023-00957-0
105. Neels JG Gollentz C Chinetti G Macrophage death in atherosclerosis: potential role in calcification Front Immunol 2023 14 1215612 10.3389/fimmu.2023.1215612 37469518
Neels JG, Gollentz C, Chinetti G. Macrophage death in atherosclerosis: potential role in calcification. Front Immunol. 2023;14:1215612.37469518 10.3389/fimmu.2023.1215612
106. Ouyang S You J Zhi C Li P Lin X Tan X Ferroptosis: the potential value target in atherosclerosis Cell Death Dis 2021 12 782 10.1038/s41419-021-04054-3 34376636
Ouyang S, You J, Zhi C, Li P, Lin X, Tan X, et al. Ferroptosis: the potential value target in atherosclerosis. Cell Death Dis. 2021;12:782.34376636 10.1038/s41419-021-04054-3
107. Yan B Belke D Gui Y Chen YX Jiang ZS Zheng XL Pharmacological inhibition of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) induces ferroptosis in vascular smooth muscle cells Cell Death Discov 2023 9 456 10.1038/s41420-023-01748-9 38097554
Yan B, Belke D, Gui Y, Chen YX, Jiang ZS, Zheng XL. Pharmacological inhibition of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) induces ferroptosis in vascular smooth muscle cells. Cell Death Discov. 2023;9:456.38097554 10.1038/s41420-023-01748-9
108. Li W Li W Leng Y Xiong Y Xia Z Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic reticulum stress DNA Cell Biol 2020 39 210 25 10.1089/dna.2019.5097 31809190
Li W, Li W, Leng Y, Xiong Y, Xia Z. Ferroptosis is involved in diabetes myocardial ischemia/reperfusion injury through endoplasmic reticulum stress. DNA Cell Biol. 2020;39:210–25.31809190 10.1089/dna.2019.5097
109. Ascherio A Willett WC Rimm EB Giovannucci EL Stampfer MJ Dietary iron intake and risk of coronary disease among men Circulation 1994 89 969 74 10.1161/01.CIR.89.3.969 8124837
Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ. Dietary iron intake and risk of coronary disease among men. Circulation. 1994;89:969–74.8124837 10.1161/01.CIR.89.3.969
110. Liao Y Cooper RS McGee DL Iron status and coronary heart disease: negative findings from the NHANES I epidemiologic follow-up study Am J Epidemiol 1994 139 704 12 10.1093/oxfordjournals.aje.a117060 8166131
Liao Y, Cooper RS, McGee DL. Iron status and coronary heart disease: negative findings from the NHANES I epidemiologic follow-up study. Am J Epidemiol. 1994;139:704–12.8166131 10.1093/oxfordjournals.aje.a117060
111. van der AD Peeters PH Grobbee DE Marx JJ van der Schouw YT Dietary haem iron and coronary heart disease in women Eur Heart J 2005 26 257 62 10.1093/eurheartj/ehi027 15618055
van der AD, Peeters PH, Grobbee DE, Marx JJ, van der Schouw YT. Dietary haem iron and coronary heart disease in women. Eur Heart J. 2005;26:257–62.15618055 10.1093/eurheartj/ehi027
112. Fang X Ardehali H Min J Wang F The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease Nat Rev Cardiol 2023 20 7 23 10.1038/s41569-022-00735-4 35788564
Fang X, Ardehali H, Min J, Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 2023;20:7–23.35788564 10.1038/s41569-022-00735-4
113. Ku E Del Vecchio L Eckardt KU Haase VH Johansen KL Nangaku M Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Kidney Int 2023 104 655 80 10.1016/j.kint.2023.05.009 37236424
Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, et al. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023;104:655–80.37236424 10.1016/j.kint.2023.05.009
114. Deng J Tang X Tang R Chen J Guo H Zhou Q Atherogenic index predicts all-cause and cardiovascular mortality in incident peritoneal dialysis patients Atherosclerosis 2023 387 117389 10.1016/j.atherosclerosis.2023.117389 38011764
Deng J, Tang X, Tang R, Chen J, Guo H, Zhou Q, et al. Atherogenic index predicts all-cause and cardiovascular mortality in incident peritoneal dialysis patients. Atherosclerosis. 2023;387:117389.38011764 10.1016/j.atherosclerosis.2023.117389
115. Heerspink HJL Ninomiya T Zoungas S de Zeeuw D Grobbee DE Jardine MJ Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials Lancet 2009 373 1009 15 10.1016/S0140-6736(09)60212-9 19249092
Heerspink HJL, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ. et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2009;373:1009–15.19249092 10.1016/S0140-6736(09)60212-9
116. Stegmayr BG Sources of mortality on dialysis with an emphasis on microemboli Semin Dial 2016 29 442 6 10.1111/sdi.12527 27528100
Stegmayr BG. Sources of mortality on dialysis with an emphasis on microemboli. Semin Dial. 2016;29:442–6.27528100 10.1111/sdi.12527
117. Maremonti F, Meyer C, Linkermann A. Mechanisms and models of kidney tubular necrosis and nephron loss. J Am Soc Nephrol. 2022;33:472–86.
118. Cozzolino M Mangano M Galassi A Ciceri P Messa P Nigwekar S Vitamin K in chronic kidney disease Nutrients 2019 11 168 10.3390/nu11010168 30646590
Cozzolino M, Mangano M, Galassi A, Ciceri P, Messa P, Nigwekar S. Vitamin K in chronic kidney disease. Nutrients. 2019;11:168.30646590 10.3390/nu11010168
119. Beulens JW Bots ML Atsma F Bartelink ML Prokop M Geleijnse JM High dietary menaquinone intake is associated with reduced coronary calcification Atherosclerosis 2009 203 489 93 10.1016/j.atherosclerosis.2008.07.010 18722618
Beulens JW, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2009;203:489–93.18722618 10.1016/j.atherosclerosis.2008.07.010
120. Geleijnse JM Vermeer C Grobbee DE Schurgers LJ Knapen MH van der Meer IM Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study J Nutr 2004 134 3100 5 10.1093/jn/134.11.3100 15514282
Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004;134:3100–5.15514282 10.1093/jn/134.11.3100
121. Belavgeni A Maremonti F Linkermann A Protocol for isolating murine kidney tubules and ex vivo cell death assays STAR Protoc 2024 5 103005 10.1016/j.xpro.2024.103005 38613777
Belavgeni A, Maremonti F, Linkermann A. Protocol for isolating murine kidney tubules and ex vivo cell death assays. STAR Protoc. 2024;5:103005.38613777 10.1016/j.xpro.2024.103005
122. Belavgeni A Meyer C Stumpf J Hugo C Linkermann A Ferroptosis and necroptosis in the kidney Cell Chem Biol 2020 27 448 62 10.1016/j.chembiol.2020.03.016 32302582
Belavgeni A, Meyer C, Stumpf J, Hugo C, Linkermann A. Ferroptosis and necroptosis in the kidney. Cell Chem Biol. 2020;27:448–62.32302582 10.1016/j.chembiol.2020.03.016
123. Amaral EP, Costa DL, Namasivayam S, Riteau N, Kamenyeva O, Mittereder L, et al. A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis. J Exp Med. 2019;216:556–70.
124. Amaral EP Foreman TW Namasivayam S Hilligan KL Kauffman KD Barbosa Bomfim CC GPX4 regulates cellular necrosis and host resistance in Mycobacterium tuberculosis infection J Exp Med 2022 219 e20220504 10.1084/jem.20220504 36069923
Amaral EP, Foreman TW, Namasivayam S, Hilligan KL, Kauffman KD, Barbosa Bomfim CC, et al. GPX4 regulates cellular necrosis and host resistance in Mycobacterium tuberculosis infection. J Exp Med. 2022;219:e20220504.36069923 10.1084/jem.20220504
125. Amaral EP Namasivayam S Queiroz ATL Fukutani E Hilligan KL Aberman K BACH1 promotes tissue necrosis and Mycobacterium tuberculosis susceptibility Nat Microbiol 2024 9 120 35 10.1038/s41564-023-01523-7 38066332
Amaral EP, Namasivayam S, Queiroz ATL, Fukutani E, Hilligan KL, Aberman K, et al. BACH1 promotes tissue necrosis and Mycobacterium tuberculosis susceptibility. Nat Microbiol. 2024;9:120–35.38066332 10.1038/s41564-023-01523-7
126. Masaldan S Clatworthy SAS Gamell C Meggyesy PM Rigopoulos AT Haupt S Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis Redox Biol 2018 14 100 15 10.1016/j.redox.2017.08.015 28888202
Masaldan S, Clatworthy SAS, Gamell C, Meggyesy PM, Rigopoulos AT, Haupt S, et al. Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis. Redox Biol. 2018;14:100–15.28888202 10.1016/j.redox.2017.08.015
127. Nishizawa H Matsumoto M Shindo T Saigusa D Kato H Suzuki K Ferroptosis is controlled by the coordinated transcriptional regulation of glutathione and labile iron metabolism by the transcription factor BACH1 J Biol Chem 2020 295 69 82 10.1074/jbc.RA119.009548 31740582
Nishizawa H, Matsumoto M, Shindo T, Saigusa D, Kato H, Suzuki K, et al. Ferroptosis is controlled by the coordinated transcriptional regulation of glutathione and labile iron metabolism by the transcription factor BACH1. J Biol Chem. 2020;295:69–82.31740582 10.1074/jbc.RA119.009548
128. Weinberg JM Bienholz A Venkatachalam MA The role of glycine in regulated cell death Cell Mol Life Sci 2016 73 2285 308 10.1007/s00018-016-2201-6 27066896
Weinberg JM, Bienholz A, Venkatachalam MA. The role of glycine in regulated cell death. Cell Mol Life Sci. 2016;73:2285–308.27066896 10.1007/s00018-016-2201-6
